Joe McCann - POINT Biopharma CEO Director
| PNTDelisted Stock | USD 9.06 0.10 1.09% |
Insider
Joe McCann is CEO Director of POINT Biopharma Global
| Age | 45 |
| Phone | 647 812 2417 |
| Web | https://www.pointbiopharma.com |
Joe McCann Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joe McCann against POINT Biopharma stock is an integral part of due diligence when investing in POINT Biopharma. Joe McCann insider activity provides valuable insight into whether POINT Biopharma is net buyers or sellers over its current business cycle. Note, POINT Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell POINT Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joe McCann over a year ago POINT Biopharma exotic insider transaction detected |
POINT Biopharma Management Efficiency
The company has Return on Asset of 0.1677 % which means that on every $100 spent on assets, it made $0.1677 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2633 %, implying that it generated $0.2633 on every 100 dollars invested. POINT Biopharma's management efficiency ratios could be used to measure how well POINT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.POINT Biopharma Global has 3.56 M in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. POINT Biopharma Global has a current ratio of 10.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for POINT to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Annie MBA | Sutro Biopharma | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Tia Bush | Centessa Pharmaceuticals PLC | 53 | |
| James Goding | Opthea | N/A | |
| Corey Goodman | Alx Oncology Holdings | 72 | |
| Eric MD | Bioatla | 60 | |
| Peter MBA | Alx Oncology Holdings | 62 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Mark Lappe | Inhibrx | 57 | |
| Michael Gerometta | Opthea | 59 | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| Julie Person | Third Harmonic Bio | 50 | |
| Rodney Young | RAPT Therapeutics | 61 | |
| Edward MD | Third Harmonic Bio | 51 | |
| PHR MBA | Immatics NV | N/A | |
| Annie Lee | Opthea | N/A | |
| Jaume Pons | Alx Oncology Holdings | 58 | |
| Kevin Capps | Crinetics Pharmaceuticals | N/A | |
| Michael Fischbach | Revolution Medicines | 43 | |
| MS MD | Oric Pharmaceuticals | 57 | |
| Gregg Keaney | Third Harmonic Bio | N/A | |
Management Performance
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 |
POINT Biopharma Global Leadership Team
Elected by the shareholders, the POINT Biopharma's board of directors comprises two types of representatives: POINT Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of POINT. The board's role is to monitor POINT Biopharma's management team and ensure that shareholders' interests are well served. POINT Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, POINT Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MPH MPH, Ex Devel | ||
| FRCSC MD, Chief Director | ||
| Ari Shomair, VP Staff | ||
| Joe McCann, CEO Director | ||
| Donna BA, VP HR | ||
| RPh Herle, Ex Affairs | ||
| BBA FCA, Chief Officer | ||
| Todd BE, Ex Operations | ||
| Justyna MSc, Chief Officer | ||
| Allan Silber, Ex Chairman | ||
| Dr JD, Sr Devel |
POINT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is POINT Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |